AVI Developing Swine Flu Drugs

Xconomy Seattle — 

AVI Biopharma, a Portland, OR-based developer of RNA-based drugs, said today it has secured a contract with the U.S. Defense Threat Reduction Agency to develop drugs for H1N1, or swine flu. Under the contract, worth as much as $5.1 million, AVI will analyze the H1N1 sequence, determine appropriate targets and identify lead and back-up candidate drugs. The company (NASDAQ: AVII) also plans to do animal tests.

By posting a comment, you agree to our terms and conditions.

5 responses to “AVI Developing Swine Flu Drugs”

  1. sunil says:

    swine flu novel drugs